http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 31 Aug 2026 09:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Coherus+to+Participate+in+Upcoming+Investor+Conferences/27002279.html <p align="left">REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc.</strong> (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences:</p> <ul type="disc"><li style="margin-bottom:12pt;">Baird 2026 Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 7:55 a.m. Eastern Daylight Time.</li><li style="margin-bottom:12pt;">H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY on Tuesday, September 15, 2026, at 11:30 a.m. Eastern Daylight Time.</li><li style="margin-bottom:12pt;">Morgan Stanley 24^th Annual Global Healthcare Conference in New York, NY on Wednesday, September 16, 2026, at 12:20 p.m. Eastern Daylight http://www.streetinsider.com/Press+Releases/Coherus+to+Participate+in+Upcoming+Investor+Conferences/27002279.html Mon, 31 Aug 2026 09:30:00 -0400 CHRS http://www.streetinsider.com/Globe+Newswire/Coherus+to+Participate+in+Upcoming+Investor+Conferences/27002279.html <p align="left">REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc.</strong> (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences:</p> <ul type="disc"><li style="margin-bottom:12pt;">Baird 2026 Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 7:55 a.m. Eastern Daylight Time.</li><li style="margin-bottom:12pt;">H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY on Tuesday, September 15, 2026, at 11:30 a.m. Eastern Daylight Time.</li><li style="margin-bottom:12pt;">Morgan Stanley 24^th Annual Global Healthcare Conference in New York, NY on Wednesday, September 16, 2026, at 12:20 p.m. Eastern Daylight http://www.streetinsider.com/Globe+Newswire/Coherus+to+Participate+in+Upcoming+Investor+Conferences/27002279.html Mon, 31 Aug 2026 09:30:00 -0400 CHRS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Aug+28/26999031.html si-local-file:///var/storage/secattach/20260828/26999031.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Aug+28/26999031.html Fri, 28 Aug 2026 17:12:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Aug+28/26999031.html si-local-file:///var/storage/secattach/20260828/26999031.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Aug+28/26999031.html Fri, 28 Aug 2026 17:12:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Coherus+Oncology%2C+Inc.+++++++++++++++/26998578.html si-local-file:///var/storage/secattach/20260828/26998578.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Coherus+Oncology%2C+Inc.+++++++++++++++/26998578.html Fri, 28 Aug 2026 16:35:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Coherus+Oncology%2C+Inc.+++++++++++++++/26998578.html si-local-file:///var/storage/secattach/20260828/26998578.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Coherus+Oncology%2C+Inc.+++++++++++++++/26998578.html Fri, 28 Aug 2026 16:35:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Coherus+Oncology%2C+Inc.+++++++++++++++/26998549.html si-local-file:///var/storage/secattach/20260828/26998549.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Coherus+Oncology%2C+Inc.+++++++++++++++/26998549.html Fri, 28 Aug 2026 16:33:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Coherus+Oncology%2C+Inc.+++++++++++++++/26998549.html si-local-file:///var/storage/secattach/20260828/26998549.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Coherus+Oncology%2C+Inc.+++++++++++++++/26998549.html Fri, 28 Aug 2026 16:33:00 -0400 CHRS O.13850153 http://www.streetinsider.com/Press+Releases/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html <p align="center"><em>– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets –</em></p> <p align="center"><em>– Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – </em></p> <p align="justify">REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc</strong>. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company’s common stock as of 5:00 p.m., New York City time, on September http://www.streetinsider.com/Press+Releases/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html Mon, 17 Aug 2026 17:33:00 -0400 A.50204413 CHRS O.00068281 O.13850153 http://www.streetinsider.com/Press+Releases/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html <p align="center"><em>– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets –</em></p> <p align="center"><em>– Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – </em></p> <p align="justify">REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc</strong>. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company’s common stock as of 5:00 p.m., New York City time, on September http://www.streetinsider.com/Press+Releases/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html Mon, 17 Aug 2026 17:33:00 -0400 A.50204413 CHRS O.00068281 O.13850153 http://www.streetinsider.com/Press+Releases/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html <p align="center"><em>– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets –</em></p> <p align="center"><em>– Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – </em></p> <p align="justify">REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc</strong>. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company’s common stock as of 5:00 p.m., New York City time, on September http://www.streetinsider.com/Press+Releases/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html Mon, 17 Aug 2026 17:33:00 -0400 A.50204413 CHRS O.00068281 O.13850153 http://www.streetinsider.com/Press+Releases/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html <p align="center"><em>– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets –</em></p> <p align="center"><em>– Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – </em></p> <p align="justify">REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc</strong>. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company’s common stock as of 5:00 p.m., New York City time, on September http://www.streetinsider.com/Press+Releases/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html Mon, 17 Aug 2026 17:33:00 -0400 A.50204413 CHRS O.00068281 O.13850153 http://www.streetinsider.com/Globe+Newswire/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html <p align="center"><em>– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets –</em></p> <p align="center"><em>– Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – </em></p> <p align="justify">REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc</strong>. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company’s common stock as of 5:00 p.m., New York City time, on September http://www.streetinsider.com/Globe+Newswire/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html Mon, 17 Aug 2026 17:33:00 -0400 A.50204413 CHRS O.00068281 O.13850153 http://www.streetinsider.com/Globe+Newswire/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html <p align="center"><em>– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets –</em></p> <p align="center"><em>– Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – </em></p> <p align="justify">REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc</strong>. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company’s common stock as of 5:00 p.m., New York City time, on September http://www.streetinsider.com/Globe+Newswire/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html Mon, 17 Aug 2026 17:33:00 -0400 A.50204413 CHRS O.00068281 O.13850153 http://www.streetinsider.com/Globe+Newswire/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html <p align="center"><em>– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets –</em></p> <p align="center"><em>– Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – </em></p> <p align="justify">REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc</strong>. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company’s common stock as of 5:00 p.m., New York City time, on September http://www.streetinsider.com/Globe+Newswire/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html Mon, 17 Aug 2026 17:33:00 -0400 A.50204413 CHRS O.00068281 O.13850153 http://www.streetinsider.com/Globe+Newswire/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html <p align="center"><em>– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets –</em></p> <p align="center"><em>– Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – </em></p> <p align="justify">REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- <strong>Coherus Oncology, Inc</strong>. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company’s common stock as of 5:00 p.m., New York City time, on September http://www.streetinsider.com/Globe+Newswire/Coherus+Oncology+Announces+Special+Dividend+of+Biosimilar+Contingent+Value+Rights/26939036.html Mon, 17 Aug 2026 17:33:00 -0400 A.50204413 CHRS O.00068281 O.13850153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Aug+17/26939001.html si-local-file:///var/storage/secattach/20260817/26939001.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Aug+17/26939001.html Mon, 17 Aug 2026 17:28:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Aug+17/26939001.html si-local-file:///var/storage/secattach/20260817/26939001.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Aug+17/26939001.html Mon, 17 Aug 2026 17:28:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Aug+17/26939007.html si-local-file:///var/storage/secattach/20260817/26939007.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Aug+17/26939007.html Mon, 17 Aug 2026 17:28:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Aug+17/26939007.html si-local-file:///var/storage/secattach/20260817/26939007.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Coherus+Oncology%2C+Inc.++++For%3A+Aug+17/26939007.html Mon, 17 Aug 2026 17:28:00 -0400 CHRS O.13850153 http://www.streetinsider.com/Earnings/Coherus+BioSciences+%28CHRS%29+Tops+Q2+EPS+by+7c/26876205.html <p>Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.19), $0.07 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $14.31 million versus the consensus estimate of $14.41 million.</p><p>For earnings history and earnings-related data on Coherus BioSciences (CHRS) <a href="http://www.streetinsider.com/ec_earnings.php?q=CHRS">click here</a>.</p> http://www.streetinsider.com/Earnings/Coherus+BioSciences+%28CHRS%29+Tops+Q2+EPS+by+7c/26876205.html Wed, 05 Aug 2026 17:49:06 -0400 CHRS http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Coherus+Oncology%2C+Inc.+++++++++++++++/26876046.html si-local-file:///var/storage/secattach/20260805/26876046.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Coherus+Oncology%2C+Inc.+++++++++++++++/26876046.html Wed, 05 Aug 2026 17:24:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Coherus+Oncology%2C+Inc.+++++++++++++++/26876046.html si-local-file:///var/storage/secattach/20260805/26876046.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Coherus+Oncology%2C+Inc.+++++++++++++++/26876046.html Wed, 05 Aug 2026 17:24:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+30/26875896.html si-local-file:///var/storage/secattach/20260805/26875896.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+30/26875896.html Wed, 05 Aug 2026 17:14:00 -0400 CHRS O.13850153 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+30/26875896.html si-local-file:///var/storage/secattach/20260805/26875896.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Coherus+Oncology%2C+Inc.++++For%3A+Jun+30/26875896.html Wed, 05 Aug 2026 17:14:00 -0400 CHRS O.13850153